Beactica Therapeutics receives FDA Orphan Drug Designation for BEA-17 for the treatment of glioblastoma
PRESS RELEASE Uppsala, Sweden – 1 February 2023 Beactica Therapeutics AB, the Swedish precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BEA-17 for the treatment of glioblastoma (GBM). BEA-17 is a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. Overexpression of LSD1 has been implicated in the pathogenesis of a variety of cancers, including GBM. There are currently no approved therapies for GBM that target this enzyme. “The FDA’s decision